Market Overview

Flu, Swine Flu, and Anti-Viral Prescriptions Well Under Norms

Share:

Pharmaceutical investors counting on a strong flu season and sales of antivirals like Tamiflu, Amantadine, and Relenza may want to prepare for disappointment… almost all of them are below the norms as well as below expectations according to data from Nataxis Bleichroeder.

Amantadine prescriptions have been under 2007’s levels since early December, and Tamiflu prescriptions fell under 2007’s totals as of the first week of January. Relenza prescriptions in 2009 are still stronger than 2007’s and 2008’s comparable season totals, but are still less than 1/6 of what they were with October’s peak.

The CDC reports that influenza reports are anywhere from ¼ to ¾ less than totals from recent years. The trend suggests that immunization efforts – and immunity following actually illness – from mid-2009 have staved off flu season this year. Or, perhaps flu season has simply not arrived yet; maybe it won’t this year.

Posted-In: flu Nataxis Bleichroeder Swine FluAnalyst Color Analyst Ratings

 

Related Articles

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
WUBABOCOM InternationalDowngrades
DLTROTR GlobalUpgrades
ARCCCompass PointDowngrades
GTYHCitiInitiates Coverage On7.0
NKEGuggenheimMaintains100.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

VMware (VMW) Wows, Raymond James Ups Estimates

Mixed Message Persists for Zions Bancorp (ZION)